Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
EBITDA Margin
161.93%
Quarterly · Period ending:
LCTX EBITDA Margin
Latest reported161.93%period ending
Latest reported161.93%period ending
LCTX Quarterly EBITDA Margin (-100.00% → 161.93%)
Quarterly ebitda margin
High-resolution chart · PNG
LCTX ebitda margin history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Margin |
|---|---|
| -3,701.3352% | |
| -2,871.2188% | |
| -1,945.1068% | |
| 0% | |
| 0% | |
| 0% | |
| -3,892.5627% | |
| -2,400% | |
| -183.3333% | |
| -200% | |
| -1,200% | |
| -175% | |
| -1,200% | |
| -180% | |
| -1,100% | |
| 0% | |
| -500% | |
| -700% | |
| -600% | |
| 0% | |
| 100% | |
| 100% | |
| -400% | |
| 0% | |
| -500% | |
| -600% | |
| -400% | |
| 0% | |
| -200% | |
| -300% | |
| -300% | |
| 0% | |
| -200% | |
| -300% | |
| -200% | |
| 0% | |
| -100% |